LFCR today
$6.40+$0.03 (+0.47%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourDescending Triangle
1 hourBullish
15 minBullish
5 minConsolidating
Daily trend turns up above $7.21
Key levels
Resistance$6.82
Resistance$6.65
Support$6.36
Support$5.96
Latest news & SEC filings
DealLifecore Biomedical's proposed merger passes US antitrust review
EarningsLifecore Biomedical Posts Q3 Fiscal 2026 Results
EarningsLifecore Biomedical posts wider quarterly loss, revenue below estimates
All LFCR news →About Lifecore Biomedical
Lifecore Biomedical is a contract manufacturer for the healthcare industry. It fills and formulates sterile injectable drugs into containers such as prefilled syringes and vials, and it assists clients with development work needed to gain regulatory clearance for their products. The company also makes and sells bulk hyaluronic acid of pharmaceutical quality, produced through fermentation rather than from animal sources. Its customers are pharmaceutical and medical device companies, and it operates mainly in the United States.
Based on the company's 10-K filed Aug 7, 2025.
Nasdaq · Healthcare
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)
What Is the Price Target for LFCR?
SEPT Low Target
$6.50
SEPT Mid Target
$6.50
SEPT High Target
$6.50
Analyst Consensus
$6.50
Is LFCR a Buy or Sell Right Now?
Thesis
- •Revenue growing 0.5% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LFCR.
Start Free Trial →Is LFCR Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
Analyst Consensus
Fair Value
$6.50
24
Moat Score
NONE
4/9
Piotroski Score
0.1
Altman Z-Score
What Is Smart Money Doing with LFCR?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Josephs Paul | director officer | Sale | 40,413 | $185K | May 20, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →LFCR Growth Story
Revenue YoY
0.5%
3yr Revenue CAGR
5.0%
EPS Growth YoY
-484.85%
FCF Growth YoY
N/A%
Revenue Trend
ACCELERATING
Dark Pool Trades for LFCR
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for LFCR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:59:31 | $6.40 | 1,200 | $$8K | BUY |
| 20:58:43 | $6.40 | 1,200 | $$8K | BUY |
| 20:58:12 | $6.39 | 1,100 | $$7K | SELL |
| 20:57:24 | $6.39 | 1,200 | $$8K | SELL |
| 20:56:21 | $6.39 | 1,200 | $$8K | SELL |
5 dark pool trades shown · $$38K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →LFCR — frequently asked questions
What is LFCR stock price today?
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) is at $6.40, up 0.47% (+$0.03) at the Nov 11, 2026 close.
Why is LFCR stock moving today?
Latest LFCR news — Nov 6, 2026: Lifecore Biomedical's proposed merger passes US antitrust review · Nov 4, 2026: Lifecore Biomedical Posts Q3 Fiscal 2026 Results
What is the LFCR price target?
The average analyst price target for LFCR is $6.50, ranging from $7 to $7, based on 1 analysts. Latest: Barrington Research maintains on Jun 16, 2026.
What do analysts rate LFCR?
Analyst ratings for LFCR: 0 Buy, 1 Hold, 2 Sell — consensus Sell.
Did LFCR beat earnings?
LFCR last reported on Nov 4, 2026: EPS -$1.08 vs -$0.28 expected — a miss of 285.7%.
Does LFCR pay a dividend?
LFCR does not currently pay a dividend.
How much debt does LFCR have?
LIFECORE BIOMEDICAL, INC. \DE\ reported $161M of debt and $23M of cash (Sep 30, 2026).
What are LFCR support and resistance levels?
Support: $6.36, $5.96, $5.86. Resistance: $6.65, $6.82, $7.21.
What are insiders doing with LFCR?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on LFCR?
Nov 6, 2026: Lifecore Biomedical's proposed merger passes US antitrust review · Nov 4, 2026: Lifecore Biomedical Posts Q3 Fiscal 2026 Results · Nov 4, 2026: Lifecore Biomedical posts wider quarterly loss, revenue below estimates